BA
NBIX icon

Bridgewater Associates’s Neurocrine Biosciences NBIX Stock Holding History

Bridgewater Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.7M Buy
205,677
+57,536
+39% +$8.54M 0.14% 117
2026
Q1 		$19.5M Sell
148,141
-1,849
-1% -$245K 0.09% 159
2025
Q4 		$21.3M Buy
149,990
+126,952
+551% +$18.4M 0.08% 192
2025
Q3 		$3.23M Buy
23,038
+14,095
+158% +$1.91M 0.01% 596
2025
Q2 		$1.12M Sell
8,943
-78,295
-90% -$8.98M ﹤0.01% 463
2025
Q1 		$9.65M Sell
87,238
-245,360
-74% -$31.1M 0.04% 265
2024
Q4 		$45.4M Buy
332,598
+197,412
+146% +$24.4M 0.21% 90
2024
Q3 		$15.6M Buy
135,186
+47,638
+54% +$6.53M 0.09% 192
2024
Q2 		$12.1M Buy
87,548
+64,397
+278% +$8.83M 0.06% 224
2024
Q1 		$3.19M Sell
23,151
-354
-2% -$48.3K 0.02% 432
2023
Q4 		$3.1M Sell
23,505
-31,490
-57% -$3.62M 0.02% 445
2023
Q3 		$6.19M Sell
54,995
-170
-0.3% -$17.9K 0.04% 314
2023
Q2 		$5.2M Sell
55,165
-4,045
-7% -$395K 0.03% 304
2023
Q1 		$5.99M Buy
+59,210
New +$6.16M 0.04% 281
2022
Q3 		– Sell
-6,503
Closed -$634K – 971
2022
Q2 		$634K Buy
6,503
+1,483
+30% +$137K ﹤0.01% 870
2022
Q1 		$471K Buy
5,020
+2,493
+99% +$211K ﹤0.01% 894
2021
Q4 		$215K Sell
2,527
-670
-21% -$61.6K ﹤0.01% 720
2021
Q3 		$307K Sell
3,197
-2,737
-46% -$259K ﹤0.01% 635
2021
Q2 		$577K Buy
+5,934
New +$569K ﹤0.01% 637

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bridgewater Associates's NBIX Position: Q2 2026 in Review

Bridgewater Associates increased its Neurocrine Biosciences (NBIX) stake by 39% in Q2 2026, buying an estimated $8.54M and bringing the position to 205,677 shares worth $34.7M. The position accounts for 0.14% of the portfolio, ranked #117.

Bridgewater Associates first reported a position in NBIX in Q2 2021 and has held it in 19 quarters since. The position peaked at $45.4M in Q4 2024. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bridgewater Associates held 205,677 shares of Neurocrine Biosciences worth $34.7M as of Q2 2026.
  • Bridgewater Associates bought 57,536 Neurocrine Biosciences shares in Q2 2026, an estimated $8.54M.
  • Neurocrine Biosciences made up 0.14% of Bridgewater Associates's portfolio in Q2 2026, its #117 holding.
  • Bridgewater Associates first reported a position in Neurocrine Biosciences in Q2 2021 and has held it in 19 quarters since.
  • Bridgewater Associates's Neurocrine Biosciences position peaked at $45.4M in Q4 2024.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.